Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188614 | 0.81 | PARP1 (0.46) | L3MBTL1ALDH1A1HTTNAAA | |
| SCHEMBL7710218 | 0.81 | HTR2C (0.33) | LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL7704961 | 0.76 | HDAC3 (0.33) | LMNAL3MBTL1MEN1ALDH1A1KMT2A | |
| SCHEMBL6302740 | 0.76 | HDAC3 (0.43) | NPSR1MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL7704912 | 0.74 | ALDH1A1 (0.45) | LMNANPSR1MAPTMEN1ALDH1A1 | |
| SCHEMBL6279353 | 0.73 | — | — | |
| SCHEMBL5188660 | 0.72 | SSTR4 (0.32) | — | |
| SCHEMBL5189245 | 0.72 | SSTR4 (0.32) | — | |
| Hydrochloric Acid SCHEMBL6279110 | 0.72 | SIGMAR1 (0.35) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5188650 | 0.72 | SIGMAR1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282610-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-6914059-B2 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2005-07-05 | — | — | US | disclosed |
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AG (DE) | 2004-01-08 | — | — | US | disclosed |
| EP-1282610-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2003-02-12 | — | — | EP | disclosed |
| WO-2001081323-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THE USE THEREOF IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006075-A1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | CYP4Z1, XDH, CYP3A5 | LMNA 1425/4885NPSR1 1903/4885MAPT 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.